Targeted transurethral microwave thermotherapy versus alpha-blockade in benign prostatic hyperplasia: outcomes at 18 months

Bob Djavan, Christian Seitz, Claus Roehrborn, Mesut Remzi, Mitra Fakhari, Matthias Waldert, Ali Basharkhah, Bernhard Planz, Mike Harik, Michael Marberger

Research output: Contribution to journalArticle

34 Citations (Scopus)

Abstract

Objectives. To compare directly the efficacy, safety, and durability of targeted transurethral microwave thermotherapy with that of alpha-blocker treatment for lower urinary tract symptoms of benign prostatic hyperplasia. Methods. In a randomized, controlled clinical trial, 52 patients with lower urinary tract symptoms due to benign prostatic hyperplasia received terazosin treatment and 51 underwent microwave treatment under topical anesthesia. The patient evaluation included the International Prostate Symptom Score, peak flow rate, and quality-of-life score before microwave treatment or initiation of terazosin treatment and at periodic intervals thereafter up to 18 months. Results. The mean International Prostate Symptom Score, peak flow rate, and quality-of-life score all improved significantly in both groups by 6 months. However, the magnitude of improvement was significantly greater in the microwave group than in the terazosin group. The significant between-group differences observed at 6 months in the mean International Prostate Symptom Score, peak flow rate, and quality-of-life score were fully maintained at 18 months, at which time the improvements in these three outcome measures were significantly greater (P <0.0005), by 35%, 22%, and 43%, respectively, in the microwave group than in the terazosin group. The actuarial rate of treatment failure at 18 months was significantly greater by sevenfold in the terazosin group. Adverse events were generally infrequent and readily manageable in both groups. Conclusions. Although the initial onset of terazosin action was more rapid, the longer term clinical outcomes of targeted microwave treatment were markedly superior. The more favorable results in patients who underwent microwave treatment were maintained for at least 18 months.

Original languageEnglish (US)
Pages (from-to)66-70
Number of pages5
JournalUrology
Volume57
Issue number1
DOIs
StatePublished - 2001

Fingerprint

Terazosin
Transurethral Resection of Prostate
Prostatic Hyperplasia
Microwaves
Prostate
Lower Urinary Tract Symptoms
Quality of Life
Therapeutics
Treatment Failure
Anesthesia
Randomized Controlled Trials

ASJC Scopus subject areas

  • Urology

Cite this

Targeted transurethral microwave thermotherapy versus alpha-blockade in benign prostatic hyperplasia : outcomes at 18 months. / Djavan, Bob; Seitz, Christian; Roehrborn, Claus; Remzi, Mesut; Fakhari, Mitra; Waldert, Matthias; Basharkhah, Ali; Planz, Bernhard; Harik, Mike; Marberger, Michael.

In: Urology, Vol. 57, No. 1, 2001, p. 66-70.

Research output: Contribution to journalArticle

Djavan, B, Seitz, C, Roehrborn, C, Remzi, M, Fakhari, M, Waldert, M, Basharkhah, A, Planz, B, Harik, M & Marberger, M 2001, 'Targeted transurethral microwave thermotherapy versus alpha-blockade in benign prostatic hyperplasia: outcomes at 18 months', Urology, vol. 57, no. 1, pp. 66-70. https://doi.org/10.1016/S0090-4295(00)00854-2
Djavan, Bob ; Seitz, Christian ; Roehrborn, Claus ; Remzi, Mesut ; Fakhari, Mitra ; Waldert, Matthias ; Basharkhah, Ali ; Planz, Bernhard ; Harik, Mike ; Marberger, Michael. / Targeted transurethral microwave thermotherapy versus alpha-blockade in benign prostatic hyperplasia : outcomes at 18 months. In: Urology. 2001 ; Vol. 57, No. 1. pp. 66-70.
@article{da58a5736cdb42f5a4f05be43b14027d,
title = "Targeted transurethral microwave thermotherapy versus alpha-blockade in benign prostatic hyperplasia: outcomes at 18 months",
abstract = "Objectives. To compare directly the efficacy, safety, and durability of targeted transurethral microwave thermotherapy with that of alpha-blocker treatment for lower urinary tract symptoms of benign prostatic hyperplasia. Methods. In a randomized, controlled clinical trial, 52 patients with lower urinary tract symptoms due to benign prostatic hyperplasia received terazosin treatment and 51 underwent microwave treatment under topical anesthesia. The patient evaluation included the International Prostate Symptom Score, peak flow rate, and quality-of-life score before microwave treatment or initiation of terazosin treatment and at periodic intervals thereafter up to 18 months. Results. The mean International Prostate Symptom Score, peak flow rate, and quality-of-life score all improved significantly in both groups by 6 months. However, the magnitude of improvement was significantly greater in the microwave group than in the terazosin group. The significant between-group differences observed at 6 months in the mean International Prostate Symptom Score, peak flow rate, and quality-of-life score were fully maintained at 18 months, at which time the improvements in these three outcome measures were significantly greater (P <0.0005), by 35{\%}, 22{\%}, and 43{\%}, respectively, in the microwave group than in the terazosin group. The actuarial rate of treatment failure at 18 months was significantly greater by sevenfold in the terazosin group. Adverse events were generally infrequent and readily manageable in both groups. Conclusions. Although the initial onset of terazosin action was more rapid, the longer term clinical outcomes of targeted microwave treatment were markedly superior. The more favorable results in patients who underwent microwave treatment were maintained for at least 18 months.",
author = "Bob Djavan and Christian Seitz and Claus Roehrborn and Mesut Remzi and Mitra Fakhari and Matthias Waldert and Ali Basharkhah and Bernhard Planz and Mike Harik and Michael Marberger",
year = "2001",
doi = "10.1016/S0090-4295(00)00854-2",
language = "English (US)",
volume = "57",
pages = "66--70",
journal = "Urology",
issn = "0090-4295",
publisher = "Elsevier Inc.",
number = "1",

}

TY - JOUR

T1 - Targeted transurethral microwave thermotherapy versus alpha-blockade in benign prostatic hyperplasia

T2 - outcomes at 18 months

AU - Djavan, Bob

AU - Seitz, Christian

AU - Roehrborn, Claus

AU - Remzi, Mesut

AU - Fakhari, Mitra

AU - Waldert, Matthias

AU - Basharkhah, Ali

AU - Planz, Bernhard

AU - Harik, Mike

AU - Marberger, Michael

PY - 2001

Y1 - 2001

N2 - Objectives. To compare directly the efficacy, safety, and durability of targeted transurethral microwave thermotherapy with that of alpha-blocker treatment for lower urinary tract symptoms of benign prostatic hyperplasia. Methods. In a randomized, controlled clinical trial, 52 patients with lower urinary tract symptoms due to benign prostatic hyperplasia received terazosin treatment and 51 underwent microwave treatment under topical anesthesia. The patient evaluation included the International Prostate Symptom Score, peak flow rate, and quality-of-life score before microwave treatment or initiation of terazosin treatment and at periodic intervals thereafter up to 18 months. Results. The mean International Prostate Symptom Score, peak flow rate, and quality-of-life score all improved significantly in both groups by 6 months. However, the magnitude of improvement was significantly greater in the microwave group than in the terazosin group. The significant between-group differences observed at 6 months in the mean International Prostate Symptom Score, peak flow rate, and quality-of-life score were fully maintained at 18 months, at which time the improvements in these three outcome measures were significantly greater (P <0.0005), by 35%, 22%, and 43%, respectively, in the microwave group than in the terazosin group. The actuarial rate of treatment failure at 18 months was significantly greater by sevenfold in the terazosin group. Adverse events were generally infrequent and readily manageable in both groups. Conclusions. Although the initial onset of terazosin action was more rapid, the longer term clinical outcomes of targeted microwave treatment were markedly superior. The more favorable results in patients who underwent microwave treatment were maintained for at least 18 months.

AB - Objectives. To compare directly the efficacy, safety, and durability of targeted transurethral microwave thermotherapy with that of alpha-blocker treatment for lower urinary tract symptoms of benign prostatic hyperplasia. Methods. In a randomized, controlled clinical trial, 52 patients with lower urinary tract symptoms due to benign prostatic hyperplasia received terazosin treatment and 51 underwent microwave treatment under topical anesthesia. The patient evaluation included the International Prostate Symptom Score, peak flow rate, and quality-of-life score before microwave treatment or initiation of terazosin treatment and at periodic intervals thereafter up to 18 months. Results. The mean International Prostate Symptom Score, peak flow rate, and quality-of-life score all improved significantly in both groups by 6 months. However, the magnitude of improvement was significantly greater in the microwave group than in the terazosin group. The significant between-group differences observed at 6 months in the mean International Prostate Symptom Score, peak flow rate, and quality-of-life score were fully maintained at 18 months, at which time the improvements in these three outcome measures were significantly greater (P <0.0005), by 35%, 22%, and 43%, respectively, in the microwave group than in the terazosin group. The actuarial rate of treatment failure at 18 months was significantly greater by sevenfold in the terazosin group. Adverse events were generally infrequent and readily manageable in both groups. Conclusions. Although the initial onset of terazosin action was more rapid, the longer term clinical outcomes of targeted microwave treatment were markedly superior. The more favorable results in patients who underwent microwave treatment were maintained for at least 18 months.

UR - http://www.scopus.com/inward/record.url?scp=0035154319&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035154319&partnerID=8YFLogxK

U2 - 10.1016/S0090-4295(00)00854-2

DO - 10.1016/S0090-4295(00)00854-2

M3 - Article

C2 - 11164146

AN - SCOPUS:0035154319

VL - 57

SP - 66

EP - 70

JO - Urology

JF - Urology

SN - 0090-4295

IS - 1

ER -